Abstract:Abstract Several cytokines involved in inflammatory pathologies signal via the Janus kinase-signal transducer and activator of transcription pathway. Four JAKs are known: JAK1, JAK2, JAK3 and TYK2. The specific activation of JAKs and STATs determines the biological effects of each cytokine. JAK1 is involved in the signalling of ‘γc’ receptor cytokines (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21), pro-inflammatory cytokines including IL-6, as well as IFN. The critical position of JAK1 downstream of these cytokines suggests that JAK1-selective inhibitors are comparable to non-selective ones, without the unwanted consequences of JAK2- or JAK3-blockade. JAK inhibition has led to a better understanding of the biology of synovial inflammation and bone homeostasis. Moreover, the efficacy of non-selective JAK inhibitors and novel JAK1-selective drugs in RA supports a role for JAK1 in its pathogenesis. JAK1-selective drugs are also showing promise in axial spondyloarthritis, suggesting that they may target additional regulatory pathways that impact cytokines such as TNF and IL-17A, which do not use JAKs. Additionally, evidence now supports a JAK1 predominance in the signalling of IL-6 and oncostatin M, and indirectly, of TNF in synovial fibroblasts, macrophages and endothelial cells. Notably, bone homeostasis is also dependent on cytokines relying on JAK1 signalling to promote receptor activator of NF-κB ligand expression in osteoblasts and T cells, contributing to osteoclastogenesis. Here, the contribution of JAK1 over other kinases is unclear. While beneficial effects of JAK inhibitors on bone erosion are supported by preclinical and clinical data, effects on new bone formation in axial spondyloarthritis requires additional study. CME: This supplement is CME Accredited. To receive a CME certificate of participation, you should: Read all the papers in the supplement Register or log in at www.paradigmmc.com/962 to complete and submit the post activity assessment. You must answer 70% of the questions correctly to earn credit. You will have unlimited opportunities to successfully complete the assessment. You will receive a maximum of 7.0 AMA PRA Category 1 CreditsTM upon successful completion of the assessment.

The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation

A new protein containing an SH2 domain that inhibits JAK kinases

JAK2 and SHP2 Reciprocally Regulate Tyrosine Phosphorylation and Stability of Proapoptotic Protein ASK1.

Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

A Novel JAK-STAT Inhibitor, 2-[(3-carbamoyl-2-thienyl)amino]-2-oxoethyl(2,6-dichlorophenyl)acetate, Suppresses Helper T Cell Differentiation in Vitro and Collagen-Induced Arthritis in Vivo.

An Alternatively Transcribed TAZ Variant Negatively Regulates JAK ‐ STAT Signaling

Atomistic insight into the inhibition mechanisms of suppressors of cytokine signaling on Janus kinase.

Small Molecule Induces Time‐Dependent Inhibition Of Stat3 Dimerization And Dna‐Binding Activity And Regresses Human Breast Tumor Xenografts

JAK1: Number one in the family; number one in inflammation?

Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression

Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity.

17-Hydroxy-Jolkinolide B Inhibits Signal Transducers And Activators Of Transcription 3 Signaling By Covalently Cross-Linking Janus Kinases And Induces Apoptosis Of Human Cancer Cells

Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function

A family of cytokine-inducible inhibitors of signalling

Discovery Of A Jak3-Selective Inhibitor: Functional Differentiation Of Jak3-Selective Inhibition Over Pan-Jak Or Jak1-Selective Inhibition

Investigation of JAKs/STAT-3 in Lipopolysaccharide-Induced Intestinal Epithelial Cells.

Function of tyrosine kinase JAK1 in IL-6-induced activation of JAK/STAT signal transduction pathway

A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal

Promiscuous Janus kinase binding to cytokine receptors modulates signaling efficiencies and contributes to cytokine pleiotropy

The Jak2/Stat3 Signal Pathway Regulates The Expression Of Genes Related To Skeletal Muscle Development And Energy Metabolism In Mice And Mouse Skeletal Muscle Cells

Role of Jak kinases and STATs in cytokine signal transduction